Parathyroid Hormone Update

Kendal L. Hamann, Nancy E Lane

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

PTH is an exciting new treatment option for postmenopausal women and hypogonadal men who have osteoporosis. As an anabolic agent that affects bone metabolism, it represents an entirely new class of medication for osteoporosis and a novel approach to reducing fracture risk. Numerous clinical trials have demonstrated increases in trabecular and cortical BMD (trabecular more than cortical) in men and women, and reduction in vertebral and nonvertebral fractures in postmenopausal women. Studies suggest that it is safe for use for up to 2 years, but further studies are needed to test longer intervals of use. Although the combination of PTH and bisphosphonates does not seem to be additive, sequential therapy of PTH followed by bisphosphonate yields maximal gains in BMD compared with combined use or monotherapy with antiresorptive agents. As our knowledge of PTH grows, this is an exciting time for researchers, clinicians, and patients who study, treat, and live with the devastating consequences of progressive osteoporosis.

Original languageEnglish (US)
Pages (from-to)703-719
Number of pages17
JournalRheumatic Disease Clinics of North America
Volume32
Issue number4
DOIs
StatePublished - Nov 2006

Fingerprint

Parathyroid Hormone
Osteoporosis
Diphosphonates
Bone Density Conservation Agents
Anabolic Agents
Research Personnel
Clinical Trials
Bone and Bones
Therapeutics

ASJC Scopus subject areas

  • Rheumatology

Cite this

Parathyroid Hormone Update. / Hamann, Kendal L.; Lane, Nancy E.

In: Rheumatic Disease Clinics of North America, Vol. 32, No. 4, 11.2006, p. 703-719.

Research output: Contribution to journalArticle

Hamann, Kendal L. ; Lane, Nancy E. / Parathyroid Hormone Update. In: Rheumatic Disease Clinics of North America. 2006 ; Vol. 32, No. 4. pp. 703-719.
@article{27a6c7f8d7c846e58d4135e7998e1205,
title = "Parathyroid Hormone Update",
abstract = "PTH is an exciting new treatment option for postmenopausal women and hypogonadal men who have osteoporosis. As an anabolic agent that affects bone metabolism, it represents an entirely new class of medication for osteoporosis and a novel approach to reducing fracture risk. Numerous clinical trials have demonstrated increases in trabecular and cortical BMD (trabecular more than cortical) in men and women, and reduction in vertebral and nonvertebral fractures in postmenopausal women. Studies suggest that it is safe for use for up to 2 years, but further studies are needed to test longer intervals of use. Although the combination of PTH and bisphosphonates does not seem to be additive, sequential therapy of PTH followed by bisphosphonate yields maximal gains in BMD compared with combined use or monotherapy with antiresorptive agents. As our knowledge of PTH grows, this is an exciting time for researchers, clinicians, and patients who study, treat, and live with the devastating consequences of progressive osteoporosis.",
author = "Hamann, {Kendal L.} and Lane, {Nancy E}",
year = "2006",
month = "11",
doi = "10.1016/j.rdc.2006.07.005",
language = "English (US)",
volume = "32",
pages = "703--719",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Parathyroid Hormone Update

AU - Hamann, Kendal L.

AU - Lane, Nancy E

PY - 2006/11

Y1 - 2006/11

N2 - PTH is an exciting new treatment option for postmenopausal women and hypogonadal men who have osteoporosis. As an anabolic agent that affects bone metabolism, it represents an entirely new class of medication for osteoporosis and a novel approach to reducing fracture risk. Numerous clinical trials have demonstrated increases in trabecular and cortical BMD (trabecular more than cortical) in men and women, and reduction in vertebral and nonvertebral fractures in postmenopausal women. Studies suggest that it is safe for use for up to 2 years, but further studies are needed to test longer intervals of use. Although the combination of PTH and bisphosphonates does not seem to be additive, sequential therapy of PTH followed by bisphosphonate yields maximal gains in BMD compared with combined use or monotherapy with antiresorptive agents. As our knowledge of PTH grows, this is an exciting time for researchers, clinicians, and patients who study, treat, and live with the devastating consequences of progressive osteoporosis.

AB - PTH is an exciting new treatment option for postmenopausal women and hypogonadal men who have osteoporosis. As an anabolic agent that affects bone metabolism, it represents an entirely new class of medication for osteoporosis and a novel approach to reducing fracture risk. Numerous clinical trials have demonstrated increases in trabecular and cortical BMD (trabecular more than cortical) in men and women, and reduction in vertebral and nonvertebral fractures in postmenopausal women. Studies suggest that it is safe for use for up to 2 years, but further studies are needed to test longer intervals of use. Although the combination of PTH and bisphosphonates does not seem to be additive, sequential therapy of PTH followed by bisphosphonate yields maximal gains in BMD compared with combined use or monotherapy with antiresorptive agents. As our knowledge of PTH grows, this is an exciting time for researchers, clinicians, and patients who study, treat, and live with the devastating consequences of progressive osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=34247111392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247111392&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2006.07.005

DO - 10.1016/j.rdc.2006.07.005

M3 - Article

C2 - 17288973

AN - SCOPUS:34247111392

VL - 32

SP - 703

EP - 719

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 4

ER -